Clinical Hold Halts Larimar’s Friedrich’s Ataxia Candidate And Financing

 
• By Joseph Haas

Looking to develop the first drug therapy for FA, Larimar gets US FDA hold due to deaths in non-human primate study. This alters clinical development timelines and fundraising plans for the firm.

Stop barrier
Larimar faces clinical hold for its Friedrich's ataxia candidate

More from Clinical Trials

More from R&D